article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed Pharmaceuticals is exploring the therapeutic potential of CBN in diseases with high unmet medical needs.

article thumbnail

Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™

Cannabis Law Report

.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Mack, Chairman and CEO of Virpax. For more information, please visit www.virpaxpharma.com. Contacts.

Safety 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Answer of the Day for Mar 21, 2023

TheAnswerPage

A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis. A Review of the Safety and Effectiveness of Select Ingredients in Compounded Topical Pain Creams.”

article thumbnail

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

Cannabis Law Report

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed Pharmaceuticals is exploring the therapeutic potential of CBN in diseases with high unmet medical needs.

article thumbnail

Answer of the Day for Jun 13, 2022

TheAnswerPage

A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis. A Review of the Safety and Effectiveness of Select Ingredients in Compounded Topical Pain Creams.”

article thumbnail

Memo to Congress: Fix the Farm Bill

Project CBD

Earlier this year, the Food & Drug Administration disclosed that it would not regulate non-pharmaceutical CBD products, thereby putting the onus on Congress to devise an appropriate regulatory framework for cannabidiol and other hemp-derived cannabinoids. Caffeine can also be found in pharmaceutical 33 and non-pharmaceutical products.)